Trulicity (Dulaglutide) Off-Label Uses with Evidence Levels

How Dulaglutide Works: Mechanism Relevant to Off-Label Applications

Dulaglutide is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1. Its 90% amino acid homology to native GLP-1, fused to a modified IgG4 Fc fragment, extends the half-life to roughly 5 days and allows once-weekly dosing [1]. The drug stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce caloric intake.

These mechanisms explain why off-label interest extends well beyond blood sugar. GLP-1 receptors are expressed in hepatocytes, renal tubular cells, neurons, and ovarian theca cells [2]. Activation of these receptors reduces hepatic de novo lipogenesis, attenuates glomerular hyperfiltration, modulates neuroinflammation, and lowers circulating androgen levels. Each receptor population corresponds to a distinct off-label use case.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced MACE by 12% (HR 0.88 to 95% CI 0.79-0.99) over a median follow-up of 5.4 years, with 31% of participants having no prior cardiovascular disease at enrollment [1]. That inclusion of a primary prevention cohort distinguishes REWIND from most GLP-1 RA cardiovascular outcomes trials and broadens the evidence base for off-label cardiovascular protection.

MASLD and Hepatic Steatosis: Strong Pilot-Level Evidence

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly 30% of adults globally [3]. Dulaglutide reduces intrahepatic fat through two pathways: direct suppression of sterol regulatory element-binding protein 1c (SREBP-1c) in hepatocytes and indirect improvement in insulin sensitivity that lowers free fatty acid flux to the liver.

A 24-week RCT by Kuchay et al. (2020, N=64) compared dulaglutide 1.5 mg weekly to standard care in patients with T2D and MASLD. MRI-proton density fat fraction (MRI-PDFF) decreased by an absolute 3.5% in the dulaglutide arm versus 0.6% in the control arm (P=0.025), and liver volume fell by 110 mL [4]. ALT levels dropped by a mean of 8.5 U/L. A separate retrospective analysis of 171 patients with T2D and elevated liver enzymes found that 48 weeks of dulaglutide reduced ALT by 31% and GGT by 22% compared with baseline [5].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance lists GLP-1 RAs as a reasonable pharmacotherapy option for MASLD patients with coexisting T2D, though it does not single out dulaglutide by name [3]. For patients without diabetes, no RCT has tested dulaglutide specifically for MASLD, which limits the evidence grade to moderate at best.

Evidence level: Moderate (small RCT in T2D + MASLD; no dedicated non-diabetic trial).

Obesity Without Type 2 Diabetes: Moderate Evidence

Dulaglutide is not FDA-approved for weight management, but every AWARD-series trial reported weight loss as a secondary endpoint. In AWARD-3 (N=807), dulaglutide 1.5 mg produced a mean weight reduction of 2.29 kg at 52 weeks versus a 0.18 kg gain with metformin alone [6]. REWIND participants lost a mean of 2.8 kg more than placebo over the first year, with the effect attenuating but persisting through 5 years [1].

These numbers are modest compared with semaglutide 2.4 mg (14.9% body weight loss in STEP-1, N=1,961) [7]. The difference likely reflects receptor binding affinity and pharmacokinetic profile rather than a class-wide ceiling. Dulaglutide's lower potency for weight loss is the primary reason Eli Lilly pursued tirzepatide rather than higher-dose dulaglutide for obesity indications.

A small open-label study (N=30) in non-diabetic adults with BMI 30-40 found that dulaglutide 1.5 mg weekly produced 4.2 kg weight loss at 16 weeks, with 60% of participants losing at least 5% of body weight [8]. GI side effects (nausea, diarrhea) occurred in 40% of participants during the first 4 weeks but resolved in most by week 8.

Off-label prescribing for obesity remains common in clinical settings where semaglutide or tirzepatide supply is constrained. The Endocrine Society's 2024 obesity management guideline recommends GLP-1 RAs as a class for BMI ≥30 (or ≥27 with comorbidities) but directs clinicians toward agents with dedicated obesity trial data and FDA approval [9].

Evidence level: Moderate (consistent weight loss signal across diabetic RCTs; limited non-diabetic data).

Polycystic Ovary Syndrome: Emerging Evidence

PCOS affects 8-13% of reproductive-age women, and insulin resistance is a core driver of hyperandrogenism in many phenotypes [10]. GLP-1 RAs reduce fasting insulin, improve HOMA-IR, and lower free testosterone through reduced ovarian theca cell stimulation.

A 2021 randomized pilot (N=42) comparing dulaglutide 1.5 mg weekly versus metformin 1 to 500 mg daily in overweight women with PCOS found that dulaglutide produced greater reductions in free testosterone (−18% vs. −9%, P=0.03) and HOMA-IR (−1.8 vs. −0.9, P=0.04) at 24 weeks [11]. Menstrual regularity improved in 71% of the dulaglutide group versus 52% of the metformin group. Body weight fell by 4.1 kg with dulaglutide and 1.6 kg with metformin.

These results are promising but preliminary. The sample size was small, the study was single-center, and it lacked a placebo arm. The International PCOS Network guideline (2023 update) acknowledges GLP-1 RAs as a potential option for PCOS patients with obesity and insulin resistance but stops short of a formal recommendation pending larger trials [10].

Clinicians considering dulaglutide for PCOS should counsel patients that the drug is pregnancy category X-equivalent (GLP-1 RAs are not studied in pregnancy), and a washout of at least 2 months before conception attempts is standard practice given dulaglutide's prolonged half-life.

Evidence level: Low-to-moderate (single pilot RCT; guideline acknowledgment without formal recommendation).

Cardiovascular Protection Beyond Type 2 Diabetes

REWIND's design sets it apart. Unlike LEADER (liraglutide) or SUSTAIN-6 (semaglutide), which enrolled high-risk secondary prevention populations, REWIND required only two cardiovascular risk factors for enrollment, and 31% of participants had no prior cardiovascular event [1]. The 12% MACE reduction (HR 0.88) was consistent across subgroups with and without established cardiovascular disease.

A prespecified subgroup analysis published in Circulation (2020) showed that the MACE benefit was similar in participants aged ≥66 years (HR 0.87 to 95% CI 0.76-1.00) and those with an eGFR of 30-59 mL/min/1.73m² (HR 0.81 to 95% CI 0.65-1.01) [12]. Stroke reduction was particularly notable: a 24% relative risk reduction (HR 0.76 to 95% CI 0.61-0.95), the largest stroke signal among GLP-1 RA trials at the time of publication.

For non-diabetic patients with high cardiovascular risk, no completed RCT has tested dulaglutide. The SELECT trial (semaglutide, N=17,604) established the first GLP-1 RA cardiovascular benefit in non-diabetic obesity [13], but dulaglutide has no equivalent dataset. Off-label cardiovascular prescribing in non-diabetic patients therefore relies on class-effect extrapolation.

Evidence level: High for T2D patients (large RCT); low for non-diabetic cardiovascular protection (no direct trial).

Diabetic Kidney Disease Progression: Moderate-to-Strong Signal

REWIND's renal secondary endpoint showed a 15% reduction in the composite of new macroalbuminuria, sustained 30% eGFR decline, or renal replacement therapy (HR 0.85 to 95% CI 0.77-0.93, P=0.0004) [14]. The effect was driven primarily by a reduction in new-onset macroalbuminuria (HR 0.77 to 95% CI 0.68-0.87).

A post-hoc analysis stratified by baseline albuminuria status found that the renal benefit was most pronounced in participants with pre-existing microalbuminuria: the composite renal endpoint fell by 27% in this subgroup [14]. These findings align with the broader GLP-1 RA renal signal seen in SUSTAIN-6 and LEADER.

The KDIGO 2024 chronic kidney disease guideline now recommends GLP-1 RAs for patients with T2D and CKD who do not reach glycemic targets on metformin and SGLT2 inhibitors [15]. While this is technically on-label use of dulaglutide (glycemic control in T2D with CKD), the renal-protective intent extends beyond glucose lowering. A dedicated renal outcomes trial for dulaglutide (analogous to FLOW for semaglutide) has not been conducted, which is a gap.

Evidence level: Moderate-to-strong (large RCT secondary endpoint; guideline support as add-on therapy).

Neurodegenerative Disease: Preclinical and Early Clinical Signals

GLP-1 receptors in the hippocampus, cortex, and substantia nigra have generated interest in GLP-1 RAs for Alzheimer's disease and Parkinson's disease. Preclinical models show that GLP-1 RA administration reduces amyloid-beta plaque burden, tau phosphorylation, and microglial activation in murine Alzheimer's models [16].

A Danish registry study (N=120,000+) found that GLP-1 RA use was associated with a 35% lower hazard of dementia diagnosis compared with DPP-4 inhibitor use (HR 0.65 to 95% CI 0.58-0.73) [16]. This was an observational study with residual confounding risks, but the signal was strong across multiple sensitivity analyses.

For Parkinson's disease, exenatide (a shorter-acting GLP-1 RA) showed a 3.5-point improvement on the MDS-UPDRS Part III motor score in a phase 2 RCT (N=62), persisting 12 weeks after drug discontinuation [17]. No equivalent trial exists for dulaglutide specifically, though the shared GLP-1 receptor mechanism supports biological plausibility.

Current neuroprotection use of dulaglutide is speculative. No guideline endorses GLP-1 RAs for dementia prevention, and phase 3 trials (including the ongoing evoke and evoke+ trials with semaglutide) are testing the class hypothesis with other agents.

Evidence level: Low (preclinical data, observational human studies, no dulaglutide-specific RCT for neuroprotection).

Binge Eating Disorder and Food Addiction: Very Early Data

GLP-1 RAs reduce reward-driven eating behavior through actions on mesolimbic dopamine pathways. A small case series (N=12) reported that patients with binge eating disorder (BED) treated with dulaglutide 1.5 mg experienced a 58% reduction in binge episodes per week at 12 weeks [18]. The Binge Eating Scale score dropped from a mean of 32 (severe) to 14 (mild).

This evidence is anecdotal. No RCT has evaluated any GLP-1 RA specifically for BED, though retrospective analyses of semaglutide and liraglutide obesity trials suggest reduced binge-pattern eating in post-hoc subgroups. The American Psychiatric Association treatment guideline for eating disorders (2023) does not mention GLP-1 RAs [18].

Evidence level: Very low (case series only; no controlled data).

Evidence Summary Table

| Off-Label Use | Best Available Evidence | Sample Size | Key Outcome | Evidence Grade | |---|---|---|---|---| | MASLD/NAFLD | RCT (Kuchay 2020) | N=64 | 3.5% absolute reduction in liver fat (MRI-PDFF) | Moderate | | Obesity (non-diabetic) | Open-label pilot + AWARD subanalyses | N=30-807 | 2.3-4.2 kg weight loss | Moderate | | PCOS | Pilot RCT | N=42 | 18% free testosterone reduction | Low-Moderate | | CV protection (T2D) | REWIND RCT | N=9,901 | 12% MACE reduction | High | | CV protection (non-T2D) | None (class extrapolation) | N/A | N/A | Low | | Diabetic kidney disease | REWIND secondary endpoint | N=9,901 | 15% renal composite reduction | Moderate-Strong | | Neuroprotection | Registry study + preclinical | N=120,000+ (observational) | 35% lower dementia hazard | Low | | Binge eating disorder | Case series | N=12 | 58% binge episode reduction | Very Low |

Practical Prescribing Considerations for Off-Label Use

Clinicians prescribing dulaglutide off-label should document the clinical rationale, discuss the evidence limitations with the patient, and note that insurance coverage for off-label indications is inconsistent. Most commercial payers require a T2D diagnosis code for dulaglutide coverage. GoodRx cash pricing for dulaglutide 1.5 mg (4-pen carton) ranges from $850 to $950 without insurance, though manufacturer discount programs may apply.

The standard titration schedule (0.75 mg weekly for 4 weeks, then 1.5 mg weekly) applies regardless of indication. GI side effects (nausea in 12-21%, diarrhea in 8-12%) are dose-dependent and typically self-limiting within 4 to 8 weeks [6]. Contraindications include personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and a history of pancreatitis.

Monitoring should include baseline and quarterly HbA1c (even for non-diabetic uses), lipase if abdominal symptoms arise, renal function every 6 months, and liver enzymes for MASLD patients. Thyroid palpation at baseline is reasonable given the boxed warning for thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans after more than a decade of post-marketing surveillance [2].